CRL | tickerfilter.com

Fundamental analysis

44%

Profitability 30%

Dept financing 43%

Liquidity 62%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.66%

1 Month

-19.38%

3 Months

-5.71%

6 Months

-22.97%

1 Year

-5.69%

2 Year

-3.74%

Key data

Stock price

$197.75

P/E Ratio

23.12

DAY RANGE

$194.55 - $200.22

EPS

$8.55

52 WEEK RANGE

$161.65 - $275.00

52 WEEK CHANGE

-$0.06

MARKET CAP

10.210 B

YIELD

N/A

SHARES OUTSTANDING

51.631 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/06/2024

BETA

1.45

PUBLIC FLOAT

AVERAGE 10 VOLUME

$497,930

AVERAGE 30 VOLUME

$890,731

Company detail

CEO: James Foster
Region: US
Website: https://www.criver.com/
Employees: 12,903
IPO year: -

Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

CRL - Charles River Laboratories International Inc.